InMed Pharmaceuticals

02/26/2026

InMed's CEO, Eric A. Adams, presents at the Renmark Financial Communications Inc. Non-Deal Roadshow.

Eric presents the preclinical studies that demonstrate how INM-901 reduces neuroinflammation associated with Alzheimer's disease. He also talks about the role of CB1 and CB2 receptors in neuroinflammation.

Watch here: https://renmark-drupal.s3.amazonaws.com/vndr/inmed-pharmaceuticals/2026-02-24-14-00-00/index.html

$INM

02/24/2026

-How is InMed's INM-901 different from other Alzheimer’s therapeutics?
-What is INM-901’s mechanism of action? How does INM-901 work?
-How does neuroinflammation affect Alzheimer’s disease?
-What were the results of the INM-901 preclinical studies?
-Does INM-901 reduce amyloid beta plaques?
-What are the next milestones for INM-901?

In this presentation, Mr. Adams speaks about how INM-901 targets the reduction of neuroinflammation. Neuroinflammation is now recognized as a key driver of Alzheimer’s disease development and progression.

In long-term preclinical studies, InMed’s INM-901 significantly reduced neuroinflammatory markers associated with Alzheimer’s disease.

In the video presentation, Mr. Adams also speaks about the upcoming development plans for INM-901 including its preparation for a pre-IND meeting with the FDA.

Watch video here: https://ow.ly/Nlj150YkzM9

$INM

In this presentation, Mr. Adams speaks about how INM-901 targets the reduction of neuroinflammation. Neuroinflammation is now recognized as a key driver of Alzheimer’s disease development and progression.

02/12/2026

InMed today reports financial results for its second quarter of fiscal year 2026, which ended December 31, 2025.

During the quarter, InMed announced the successful completion of pharmacokinetic studies in clinically relevant in vivo models for INM-901. This marked the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program.

Full news release: https://ow.ly/4PrR50Ye8EZ

$INM

02/12/2026

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

“We are pleased with the steady progress across our pharmaceutical pipeline as we look ahead to pursuing pre-IND meetings with the FDA in 2026. In our INM-901 program, compelling data from the preclinical studies demonstrated a significant reduction in key neuroinflammatory markers, reinforcing neuroinflammation as the central focus of our drug development activities.” ~ Eric A. Adams, CEO

Read full news release here: https://ow.ly/hZEk50Ye8Bw

$INM

12/18/2025

: InMed Announces Results of 2025 Annual General and Special Meeting

Read news release here: https://ow.ly/RGAw50XLfuS

$INM

12/12/2025

InMed presents at the Life Sciences Virtual Investor Forum. CEO Eric A. Adams gives a company update and shares the preclinical data on InMed's lead compound INM-901 for disease.

Presentation available on demand here: https://ow.ly/pXUO50XICg0

$INM

12/04/2025

What is the role of neuroinflammation in Alzheimer's disease development and progression?

This panel of disease experts talk about what to expect in Alzheimer's research in the next few years and why is an important target for novel Alzheimer's treatments.

Discussion here: https://ow.ly/TqVq50XC36B

$INM

Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, joins a panel of experts to speak about recent breakthroughs in Alzheimer’s disease research and the effects ...

12/01/2025

Summary of InMed's INM-901 Pharmacokinetics Study:

-Over a seven-day dosing period, study demonstrated robust bioavailability with INM-901 achieving what is anticipated to be therapeutic levels of systemic exposure
-Neurological assessments evaluating general attitude, behavior, and motor function revealed no adverse neural or behavioral effects
-InMed has completed additional CMC development to scale manufacturing in preparation for pre-IND meeting with FDA

More here: https://ow.ly/MVST50XAhoY

$INM

11/28/2025

Video Replay on Demand: InMed Presents at the Life Sciences Investor Forum.

InMed's CEO Eric A. Adams gives a progress update on InMed’s pipeline including recent data from the Company’s leading pharmaceutical program INM-901 in the treatment of Alzheimer’s disease. The new preclinical data was recently presented at the Alzheimer’s Association International Conference (AAIC) 2025, the world’s leading forum for Alzheimer’s disease and dementia research.

https://www.inmedpharma.com/learn/inmed-presents-at-the-2025-life-sciences-investor-forum/

$INM

InMed's Eric A. Adams presents at the 2025 Life Sciences Investor Forum and gives an update on lead program INM-901 for Alzheimer's disease.

11/24/2025

What is neuritogenesis?

In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.

Video here: https://www.inmedpharma.com/learn/what-is-neuritogenesis-how-does-neuritogenesis-affect-alzheimers-disease/

$INM

In this video, InMed's CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.

11/21/2025

InMed has conducted several in vitro and in vivo studies to test the pharmacological effects of INM-901 in Alzheimer’s disease preclinical models with promising results demonstrating disease-modifying effects.

A summary of INM-901 preclinical study results:

➡️ Demonstrates neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study
➡️ Demonstrates significant reduction in inflammatory biomarkers associated with Alzheimer’s, including IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2 & NfL
➡️ May have a direct impact on neuroinflammation independent of the influence of amyloid beta or tau aggregation
➡️ Demonstrates an ability to promote neurite outgrowth, signifying the potential to improve neuronal function, a potential breakthrough in the treatment of Alzheimer’s disease
➡️ Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function
➡️ Demonstrates robust bioavailability in in vivo models, achieving what is anticipated to be therapeutic levels of systemic exposure
➡️ Additional mRNA data supports the observations made in behavior studies in locomotor activity, cognition and memory.

More about InMed's INM-901 program here: https://www.inmedpharma.com/pharmaceutical/inm-901-for-alzheimers-disease/

$INM

11/20/2025

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step

Alzheimer’s disease research experts come together for this informative session. Learn about:

-Role of neuroinflammation in the development of cognition-impairing disease
-Biological pathways to developing drugs to address neuroinflammation
-Why neuroinflammation is an important target for novel Alzheimer’s treatments
-Importance of patient diversity in clinical trial design
-Scanning the horizon – what to expect in the next 5 years

Watch Fierce Biotech webinar here: https://ow.ly/WV4C50XurIP

$INM

Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu, joins a panel of experts to speak about recent breakthroughs in Alzheimer’s disease research and the effects ...